



The Novel Insight of Programmed Death Ligand 1 Over-Expression in Tuberculosis Patients From System Biology

Masoud Keikha^{1,2*}

¹Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

²Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding Author: Masoud Keikha, Tel: +989386836425, Email: masoud.keykha90@gmail.com

Received: 8 June 2018, Accepted: 4 December 2018, ePublished: 29 December 2018

Dear Editor,

Tuberculosis (TB) remains one of the 10 leading causes of morbidity and mortality in the world. It is estimated that 2 billion of world's population are infected with *Mycobacterium tuberculosis* as asymptomatic (latent TB) during their lives, of whom, 5-10% progress to active TB (1). The immune response influenced host reaction to *M. tuberculosis* infection; particularly CD4⁺ T cells that are responsible for resistance to TB infection but there are several questions that remain unanswered about dysregulation of the balance between protection and reactivation of previous TB infection; understanding this process lead to development of monitoring of TB progression in latent-TB infection (LTBI) and appropriate treatment (2,3).

The programmed cell death protein 1 (PD-1 or CD279) is a surface molecule which interacts with PD-L1, PD-L2, CD80, CD86 or PDCD1 surface receptors followed by down-regulating the immune system via promoting apoptosis or reducing T regulatory cell death (T regulatory inhibits Th1 activities by suppressing cytokine, e.g. IL-10 and TGF- β) (2,4). According to the literature, the PD-1/PD-L1 interaction dysregulates IFN- γ production and suppresses CD8⁺ T lymphocytes via stimulating apoptosis reaction (4,5). In addition, the PD-1 is over-expressed in active TB patients compared with healthy individuals (4,6). PD-1 overexpression reduces the expression of IFN- γ and development of TB progression in LTBI cases (4). In the present study, we analyzed the PD-1 and the expression of its ligands among active-TB and LTBI patients and healthy individuals as well as changes in IFN- γ , FOXP3, IL-10 and TGF- β in these population using a system biology study.

First, the gene expression profiles of active-TB and LTBI patients and healthy individuals were obtained from Gene Expression Omnibus (GEO) database (Accession number: GDS4966, GPL570 platform). Then, the GEO2R and

GEO profiles were employed to determine differentially expressed genes (DEGs) of PD-1, PD-L1, PD-L2, PDCD1, CD80, CD86, IFN- γ , Foxp3, IL-10 (based on the KEGG pathway, hsa04151) and TGF- β for three categories using Benjamini-Hochberg FDR-adjusted *P* values <0.05. In addition, the protein-protein interaction network (PPIN) was constructed using STRING (Search Tool for the Retrieval of Interacting Genes) online server. According to our analysis, the PD-1/PD-L2 is over-expressed in active-TB compared to LTBI and healthy individuals, which has also been confirmed by previous reports (2,4-6). In addition, IFNG is down-regulated in active-TB (Table 1). In contrast, PF-L1, PDCD1 and CD4⁺ T cells on surface molecules CD80 and CD86 were down-expressed in active-TB group, which could be the cause of CD4⁺ T cell death under the influence of PD-1 over-expression in this group or the potential PD-1 interaction with alternative receptors but the expression amount of Bax (apoptotic biomarker) was down-expressed in active-TB patients, which confirms increased cell death (due to PD-1, etc) in active TB patients. But Foxp3, IL-10 and TGF- β were down-regulated in active-TB patients compared to LTBI patients and healthy individuals. According to previous reports, Foxp3 is a reliable biomarker for production of T regulatory cells that is recruited in granuloma lesion in the lungs of TB patients and is decreased in peripheral blood mononuclear cells (7,8); therefore, the decrease in the expression of Foxp3, IL-10 and TGF- β in this study is logical (Table 1).

The PPIN confirmed the close relationship between PD-1 and CD4⁺ T cell receptors that influenced acquired immune system, particularly CD4⁺ T cells. According to the interaction network, the PD-1 could influence PDCD1, PDCD1LG2, CD274 and CD80 surface molecules which regulates the immune system including T cell stimulation, cell death and proliferation, IL-2

Table 1. Different Profiles of Gene Expression in Active-TB, LTBI and Health Groups

Genes	Expression Amounts in 3 categorizations		
	Active-TB	LTBI	Health donors
<i>PD-1</i>	84.44	82.33	81.66
<i>PD-L1</i>	72.77	81.5	82.16
<i>PD-L2</i>	18	11	11
<i>PDCD1</i>	37.66	48.33	47.33
<i>CD80</i>	38.11	71.66	70.16
<i>CD86</i>	87.55	92.33	92.83
<i>IFNG</i>	13.44	15.66	22.83
<i>Foxp3</i>	19.88	24	17.5
<i>IL-10</i>	44.55	60.16	76.16
<i>TGF-β</i>	63.33	66	66.33
<i>Bax</i>	82.66	74.5	71.66

induction and pro-inflammatory cytokines production. There are PD-1 and its ligands in the central nodes which have been surrounded by numerous genes which indicates vital cellular processes such as apoptosis, T regulatory production, p53 signaling pathway, and inflammatory cytokines (Figure 1).

In summary, the PD-1 is over-expressed in active TB patients compared to LTBI patients and healthy individuals, which stimulates CD4+ T cell death via apoptosis and production of T regulatory cells. Overall, our system biology study confirmed previous reports that have indicated the PD-1 is over-expressed in active-TB patients. In addition, there are novel insights about numerous immune system changes mediated by PD-1 over-expression that lead to progression from LTBI to active-TB particularly T regulatory production or CD4+ T cell apoptosis during TB pathogenesis. The PD-1 is considered as a reliable biomarker for TB progression and as a novel therapeutic target for TB treatment.

Ethical Approval

The Ethics Committee of Mashhad University of Medical Sciences approved the study.

Conflict of Interest Disclosures


None.

Funding/Support

None.

References

1. Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.

**Figure 1.** The Protein-Protein Interaction Networks of PD-1 and its Related Protein During Tuberculosis Pathogenesis.

1. Lancet Infect Dis. 2018;18(8):e228-e38. doi: [10.1016/s1473-3099\(18\)30134-8](https://doi.org/10.1016/s1473-3099(18)30134-8).
2. Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E, et al. Programmed death (PD)-1: PD-ligand 1/ PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. *J Immunol.* 2008;181(1):116-25. doi: [10.4049/jimmunol.181.1.116](https://doi.org/10.4049/jimmunol.181.1.116).
3. Young D, Stark J, Kirschner D. Systems biology of persistent infection: tuberculosis as a case study. *Nat Rev Microbiol.* 2008;6(7):520-8. doi: [10.1038/nrmicro1919](https://doi.org/10.1038/nrmicro1919).
4. Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, et al. PD-1 expression on Mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis. *Front Immunol.* 2018;9:1995. doi: [10.3389/fimmu.2018.01995](https://doi.org/10.3389/fimmu.2018.01995).
5. Pollock KM, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, et al. PD-1 expression and cytokine secretion profiles of Mycobacterium tuberculosis-specific CD4+ T-cell subsets; potential correlates of containment in HIV-TB co-infection. *PLoS One.* 2016;11(1):e0146905. doi: [10.1371/journal.pone.0146905](https://doi.org/10.1371/journal.pone.0146905).
6. McNab FW, Berry MP, Graham CM, Bloch SA, Oni T, Wilkinson KA, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. *Eur J Immunol.* 2011;41(7):1941-7. doi: [10.1002/eji.201141421](https://doi.org/10.1002/eji.201141421).
7. Ghazalsolefala R, Rezaee SA, Rafatpanah H, Vakili R, Ghazvini K, Heidarnejad F, et al. Evaluation of CD4+ CD25+ FoxP3+ regulatory T cells and FoxP3 and CTLA-4 gene expression in patients with newly diagnosed tuberculosis in northeast of Iran. *Jundishapur J Microbiol.* 2015;8(4):e17726. doi: [10.5812/jjm.8\(4\)2015.17726](https://doi.org/10.5812/jjm.8(4)2015.17726).
8. Keikha M. The Ambiguous Role of Treg Cells in Mycobacterium tuberculosis Pathogenesis. *Jentashapir J Health Res.* 2018;9(5):e83541. doi: [10.5812/jjhs.83541](https://doi.org/10.5812/jjhs.83541)